SEC Form 10-Q filed by Vigil Neuroscience Inc.
$VIGL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2023 | $13.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 10/18/2023 | $23.00 | Mkt Outperform | JMP Securities |
| 3/31/2023 | $15.00 | Buy | Mizuho |
| 9/16/2022 | $19.00 | Outperform | Wedbush |
| 8/29/2022 | $24.00 | Buy | H.C. Wainwright |
| 2/1/2022 | $17.00 | Equal-Weight | Morgan Stanley |
| 2/1/2022 | $23.00 | Buy | Guggenheim |
| 2/1/2022 | $24.00 | Buy | Stifel |
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will be presenting at the following conferences in November: Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate/Time: Monday, November 18th at 4:45 p.m. ET Jefferies London Healthcare ConferenceFormat: Fireside ChatDate/Time: Wednesday, November 20th at 8:30 a.m. GMT The webcasts will also be available on the Company's website in the "Investors" section under "Events & Presentations." Archived webcasts will be available for
- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer's Disease on track for first quarter of 2025 - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024, and provided an update on recent progress. "Our accomplishments in the third quarter have provided significant momentum as we continue to
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 11, 2024, at 10:30 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company's website in the "Investors" section under "Events & Presentations." An archived webcast will be available for approximately 90 days following the event. . About Vigil Neuroscience Vigil Neuroscience
HC Wainwright & Co. analyst Andrew Fein reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Buy and maintains $17 price target.
Vigil Neuroscience Inc. (NASDAQ:VIGL) released interim data on Wednesday from its ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers. VG-3927 is a novel small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease (AD) patients, including some who carry TREM2 and other disease-associated variants. The interim safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile support the continued clinical development of VG-3927 as a potential once-daily oral therapy for Alzheimer's disease. Additionally, these data showed that VG-3927 demonstrated functional and dur
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r
10-Q - Vigil Neuroscience, Inc. (0001827087) (Filer)
8-K - Vigil Neuroscience, Inc. (0001827087) (Filer)
8-K - Vigil Neuroscience, Inc. (0001827087) (Filer)
Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously
JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00
Mizuho initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $15.00
SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
SC 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)
SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed biotech industry executive Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer – WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseas
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)